Drug Pricing

On Jan. 17, just days before leaving office, the Biden administration announced the next 15 prescription drugs dispensed through Medicare Part D that will be subject to price controls on Jan. 1, 2027, under the terms of the Inflation Reduction Act. Among them is the blockbuster semaglutide, a prescription medication ...

Just three days before President Biden left office, his appointees tried to tie incoming Trump staffers’ hands on a health policy decision that affects millions of Americans and tens of billions in federal spending. On January 17, the Centers for Medicare & Medicaid Services announced a new list of 15 ...

California State Senator Scott Wiener, D-San Francisco, recently introduced a bill aimed at reining in pharmacy benefit managers (PBMs), the middlemen largely responsible for the dysfunction plaguing our nation’s prescription drug market. Wiener’s effort should attract the support of lawmakers on both the left and right. By cracking down on ...

CMS recently announced the next 15 drugs that will be subject to price negotiations under the Inflation Reduction Act of 2022 (IRA). These are negotiations in name only because CMS can levy penalties on any manufacturer that fails to comply with the process. Since the penalties include an excise tax ...

PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027.  The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...

Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden  | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move. Expanding coverage to these patient groups makes sense. Read the entire op-ed here.

Biden administration is proposing that Medicare and Medicaid cover Ozempic and other GLP-1 drugs for weight loss. It’s unclear what the Trump administration will do with its predecessor’s proposal. Democrats may be trying to goad Medicare under Trump into slapping price controls on GLP-1s — something progressives have long wanted ...

Time to Bring Hospital Pricing Out the Shadows, It’s Long Overdue Just one in five hospitals is complying with federal price-transparency rules today, according to a new report from the group Patient Rights Advocate. Put differently, hospitals are keeping the prices of their services secret in violation of the law. ...